The risks and benefits of HPV vaccination

JAMA. 2009 Aug 19;302(7):795-6. doi: 10.1001/jama.2009.1215.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Ethics, Business
  • Female
  • Financial Support
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Humans
  • Marketing
  • Papillomavirus Infections / prevention & control
  • Papillomavirus Vaccines* / adverse effects
  • Risk Assessment
  • United States
  • Uterine Cervical Neoplasms / prevention & control
  • Uterine Cervical Neoplasms / virology
  • Vaccination / standards

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Vaccines